Search

Background: In the new era the COVID-19 disease became a world-wide pandemic in a short time, medical practice is predicted to be affected due to the both physician and patient tendencies, and usage of limited diagnosis and treatment opportunities for the outbreak In this study we investigated the characteristics of the patients who received chemotherapy (CT) or supportive treatments at the Hacettepe University Oncology Hospital Daily Treatment Unit in the first 60 days after the first case was detected in Turkey Methods: Patients recieved any CT or any kind of supportive treatment between 11th March 2020-10th May 2020 and 11th March 2019-10th May 2019 were included to the study Demographic properties and diagnoses of the patients, number of protocols and sessions applied, and non-chemotherapy treatments were investigated retrospectively Results: Between 11 th March 2020 and 10th May 2020 the average daily chemotherapy (CT) sessions apllied decreased by 7% compared to the same period of the previous year Patients receiving treatment for the first time decreased by 50% in the COVID period comparing to the last year and decreased from 146 to 73 (p=0 03) (Table) Supportive hydration treatments applied to an average of 8 3 patients daily decreased by 55% to an average of 3 8 per day In the 2019 a total of 137 transfusions were performed while in the period of COVID-19, the number of transfusions decreased by 29% to 98 [Formula presented] Conclusions: A minimal change was observed in the total number of chemotherapy applied during the pandemic period It is imperative that treatment units continue to work because most of the treatments in oncology practice is not postponable Decrease in patients who received treatment for the first time is a parameter that should be followed closely Hesitation of the patients having symptoms to consult a doctor or prolong the diagnosis period may prevent the diagnosis of curable disease on time Similarly, delay in patients' access to supportive treatments, may lead to an increase morbidity and mortality Legal entity responsible for the study: The authors Funding: Has not received any funding Disclosure: All authors have declared no conflicts of interest

Background Outpatient palliative care (OPC) offers improved symptom control, quality of life and even survival. OPC clinics may be embedded in the oncology clinic or independent. We herein present our experience with an embedded OPC clinic led by a medical oncologist, an internist and a nurse in Hacettepe University Medical Oncology Clinic. Methods Patients who were referred by their oncologist or those who had severe symptoms and applied without referral were admitted. Besides baseline history and physical exam, Edmonton Symptom Assesment Scale (ESAS), Nutritional risk screening 2002 and visual analog scale for pain were routinely assessed except for patients with acute symptoms requiring urgent intervention. Interventions and consultations were recorded for all patients. Results A total of 174 patients were seen in our clinic within the first 5 months. Demographic features are shown in the table. The chief complaints were pain (26%), nausea and vomiting (13%) and decreased feeding (9%). Besides their chief complaints, patients had a median of 4 (min 0- max 8) other severe (ESAS score of > 5) complaints. The most frequent interventions were intravenous hydration, analgesic and/or antiemetic administration and prescription (n = 66), nutritionist (n = 62) and pain specialist (n = 59) consultations. Thirty-three patients (19 %) were referred for immediate hospitalization. The overall mortality within the first 30 days after the first OPC visit was 17%. Table . 1615P Baseline characteristics of the applied patients Median Age (minimum- maximum) 60.5 (17-91) Male/Female 94 (58%)/80 (42%) Patient Stages Stage 1: 4 (2.3%) Stage 2: 7 (4%) Stage 3: 18 (10.3%) Stage 4: 157 (73.6%) ECOG Performance Status ECOG 0: 19 (10.9%) ECOG 1: 50 (28.7%) ECOG 2: 36 (20.7%) ECOG 3: 40 (23%) ECOG 4: 25 (14.4%) Tumor Sites Gastrointestinal: 53 (30.5%) Lung: 43 (24.7%) Genitourinary: 15 (8.6%) Breast: 14 (8%) Gynecologic: 11 (6.3%) Head and Neck Cancer: 9 (5.2%) Other: 29 (16.7%) Conclusions Our initial experience with the embedded OPC clinic mostly included patients with advanced disease, multiple severe symptoms and high risk of mortality. Management of these patients within the oncology clinic may address palliative care needs of these patients, provide timely therapeutic interventions, reduce unnecessary diagnostic tests and diminish emergency department applications by these patients. Legal entity responsible for the study The authors. Funding Has not received any funding. Disclosure All authors have declared no conflicts of interest.

Background Impaired DNA damage response (DDR) mechanisms and subsequent genomic instability is associated with carcinogenic process itself, but it also results in sensitivity of tumor cells to certain drugs and can be exploited to treat cancer by inducing deadly mutations or mitotic catastrophe. As a result, BRCA1/2 testing is recommended for a group individuals with breast/ovarian cancer. Methods In this study, we retrospectively invesitigated clinicopathologic features of 303 breast cancer patients tested for BRCA 1/2 mutation in an oncology institute. NCCN recommendations are used to select patients to be tested for BRCA mutations. Results A total of 303 patients were analysed for BRCA 1/2 mutations. Median age of the patients at diagnoses were 40 (21-65). Family history for BRCA related cancers were detected in 120 patients (39.6%). BRCA 1/2 mutations have been shown in 98 of 303 patients (32.3%). Of 98 BRCA mutated patients, 43 had pathogenic BRCA1 mutation, 39 had pathogenic BRCA2 mutation, 11 had variant of uncertain significance (VUS) BRCA2 mutation, 3 had VUS BRCA1 mutation and 2 had pathogenic BRCA1 and 2 mutations. Molecular subtypes of tumors have been shown in Table. Table . 316P Molecular subtypes of tumors BRCA Status HR(+)/ HER2(-), N(%) HR(+)/ HER2(+), N(%) HR(-)/ HER2(+), N (%) Triple(-), N (%) N/A,N(%) BRCA1 18 (41.8%) 2 (4.6%) 0 22 (51.1%) 1 (2.3%) BRCA2 25 (64.1%) 3 (7.7%) 0 6 (15.3%) 5 (12.8%) BRCA1 VUS 2 (66.7%) 0 0 1 (33.3%) 0 BRCA2 VUS 11 (100%) 0 0 0 0 BRCA1 + 2 0 1 (50%) 0 1 (50%) 0 BRCA mut (-) 126 (61.4%) 25 (12.1%) 12 (5.8%) 32 (15.6%) 10 (4.8%) TOTAL 182 (60%) 31 (10.2%) 12 (3.9%) 62 (20.4%) 16 (5.2%) Twelve of 98 BRCA mutated patients (12.2%) were de novo metastatic while 15 patients (15.3%) faced with metastatic disease during follow-up. In the BRCA mutated group there was significantly high rate of metastatic disease has been detected comparing BRCA non-mutated group (27.5% vs %16.5% respectively, p = 0.026). Metastatic BRCA mutant patients showed worse OS numerically but data is not statistically significant (P = 0.894). Nine patients were diagnosed with contralateral breast cancer, and 3 patients was diagnosed with BRCA-related cancers during follow-up. Prophylactic surgery (contralateral mastectomy and/or oophorectomy) was performed in 32 of 98 patients. Conclusions According to this retrospective study, BRCA mutant patients tend to have worse clinical and pathological features comparing age-matched controls. Legal entity responsible for the study Sercan Aksoy. Funding Has not received any funding. Disclosure All authors have declared no conflicts of interest.